SCHEMBL2534792

SCHEMBL2534792

O=C(O)C=Cc1cc(-c2ccccc2[N+](=O)[O-])ccc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.57
PTGER2 P43116 6/20 0.57
PTGER3 P43115 5/20 0.57
PTGER1 P34995 4/20 0.57
MAPT P10636 3/20 0.50
LTB4R Q15722 1/20 0.48
LTB4R2 Q9NPC1 1/20 0.48
BACE1 P56817 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GLA P06280 1/20 0.43
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534789 1.00 PTGER4 (0.57) PTGER4PTGER2PTGER3PTGER1MAPT
SCHEMBL2531020 0.85 ERN1 (0.47) MAPTKDM4EMEN1KMT2ACTSV
SCHEMBL2537505 0.81 PTGER4 (0.67) PTGER4PTGER2PTGER3PTGER1MAPT
SCHEMBL2537502 0.81 PTGER4 (0.67) PTGER4PTGER2PTGER3PTGER1MAPT
SCHEMBL7761815 0.79 MCL1 (0.55) PTGER1MAPTMEN1KMT2ACTSV
SCHEMBL8786625 0.78 KDM4E (0.63) PTGER4PTGER2PTGER3PTGER1BACE1
SCHEMBL8786629 0.78 KDM4E (0.63) PTGER4PTGER2PTGER3PTGER1BACE1
SCHEMBL344775 0.76 PTGER4 (0.70) PTGER4PTGER2PTGER3PTGER1LTB4R
SCHEMBL344776 0.76 PTGER4 (0.70) PTGER4PTGER2PTGER3PTGER1LTB4R
SCHEMBL344657 0.75 PTGER3 (0.68) PTGER4PTGER2PTGER3PTGER1LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 PTGER4 3046/4885PTGER2 2944/4885PTGER3 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.